These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

421 related items for PubMed ID: 22095397

  • 1. Dry powder inhaler device influence on carrier particle performance.
    Donovan MJ, Kim SH, Raman V, Smyth HD.
    J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
    [Abstract] [Full Text] [Related]

  • 2. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations.
    Donovan MJ, Smyth HD.
    Int J Pharm; 2010 Dec 15; 402(1-2):1-9. PubMed ID: 20816928
    [Abstract] [Full Text] [Related]

  • 3. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M, Ho S, Muddle J, Buttini F, Parry M, Hammond M, Forbes B.
    Int J Pharm; 2015 Jul 25; 490(1-2):360-7. PubMed ID: 25987210
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH, Hagedoorn P, Gjaltema D, Goede J, Frijlink HW.
    Int J Pharm; 2006 Mar 09; 310(1-2):81-9. PubMed ID: 16442246
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Lactose characteristics and the generation of the aerosol.
    Pilcer G, Wauthoz N, Amighi K.
    Adv Drug Deliv Rev; 2012 Mar 15; 64(3):233-56. PubMed ID: 21616107
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
    Jetzer MW, Schneider M, Morrical BD, Imanidis G.
    J Pharm Sci; 2018 Apr 15; 107(4):984-998. PubMed ID: 29247741
    [Abstract] [Full Text] [Related]

  • 13. The clinical relevance of dry powder inhaler performance for drug delivery.
    Demoly P, Hagedoorn P, de Boer AH, Frijlink HW.
    Respir Med; 2014 Aug 15; 108(8):1195-203. PubMed ID: 24929253
    [Abstract] [Full Text] [Related]

  • 14. The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices.
    Ooi J, Gill C, Young PM, Traini D.
    Curr Drug Deliv; 2015 Aug 15; 12(1):40-6. PubMed ID: 25146438
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Relationship Between the Permeability and the Performance of Carrier-Based Dry Powder Inhalation Mixtures: New Insights and Practical Guidance.
    Shalash AO, Khalafallah NM, Molokhia AM, Elsayed MMA.
    AAPS PharmSciTech; 2018 Feb 15; 19(2):912-922. PubMed ID: 29063377
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
    Kaialy W, Martin GP, Larhrib H, Ticehurst MD, Kolosionek E, Nokhodchi A.
    Colloids Surf B Biointerfaces; 2012 Jan 01; 89():29-39. PubMed ID: 21962946
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.